by In2Pharma | Sep 2, 2024 | News
Belgium Annex IA: 0,2% Cannabis has been changed to 0,3% CannabisThe below substances are added :2-METHYL-AP-237ETAZENE (ETODESNITAZENE)ETONITAZEPYNEPROTONITAZENE Annex IIB: The below substances are added:ADB-BUTINACAalpha-PiHP3-METHYLMETHCATHINONE (3-MMC) Annex IIC:...
by In2Pharma | Aug 26, 2024 | News
Luxembourg The IML Code outlines the ethical standards that its members have committed to follow when promoting medicines to healthcare professionals (HCPs) and engaging with HCPs, healthcare organizations (HCOs), and patient organizations (POs). These guidelines...
by In2Pharma | Aug 26, 2024 | News
Europe We would like to inform you of a significant new EU regulation—the Ecodesign for Sustainable Products Regulation (ESPR)—which came into force on July 18th, 2024, replacing the previous 2009 legislation. This regulation is designed to make products more...
by In2Pharma | Aug 23, 2024 | News
Luxembourg La Division de la Pharmacie et des Médicaments de la Direction de la Santé (DPM) has published updated instructions for the distribution of DHPC (version 3.0 – 06/2024) and aRMM (version 4.0 – 06/2024) in Luxembourg. A change in the updated version is...
by In2Pharma | Aug 23, 2024 | News
Europe The Commission Regulation (EU) 2024/2041, dated 29 July 2024, which amends Regulation (EU) No 432/2012 concerning the health claim for monacolin K from red yeast rice, was published in the Official Journal on 30 July. The European Commission’s regulation...
by In2Pharma | Aug 8, 2024 | News
The Netherlands Disclosure of financial interactions between pharmaceutical companies and healthcare professionals and organisations, and patient organisations can be reported in the Transparency Register Zorg in the Netherlands (www.transparantieregister.nl)....
